Last reviewed · How we verify
THP-00102
THP-00102 is a small molecule that targets the molecular target.
THP-00102 is a small molecule that targets the molecular target. Used for Condition 1.
At a glance
| Generic name | THP-00102 |
|---|---|
| Also known as | Micardis Tab. 80mg |
| Sponsor | THPharm Corp. |
| Target | molecular target |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of THP-00102 is not well understood, but it is believed to work by binding to the molecular target and inhibiting its activity.
Approved indications
- Condition 1
Common side effects
- Adverse event 1
Key clinical trials
- A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension (PHASE3)
- A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- THP-00102 CI brief — competitive landscape report
- THP-00102 updates RSS · CI watch RSS
- THPharm Corp. portfolio CI